Track Q32 Bio Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Q32 Bio Inc. QTTB Open Q32 Bio Inc. in new tab

5.75 USD
P/E
2.27
EPS
2.78
P/B
1.93
ROE
157.18
Beta
-1.27
Target Price
14.33 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 5, 2026
P/E2.27
EPS2.78
Book Value3.27
Price to Book1.93
Debt/Equity29.47
% Insiders3.928%
Estimates
Forward P/E-1.18
Forward EPS-5.36
Target Mean Price14.33

DCF Valuation

Tweak assumptions to recompute fair value for Q32 Bio Inc. (QTTB)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Q32 Bio Inc. Logo Q32 Bio Inc. Analysis (QTTB)

Healthcare Official Website Stock

Is Q32 Bio Inc. a good investment? Q32 Bio Inc. (QTTB) is currently trading at 5.75 USD. Market analysts have a consensus price target of 14.33 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 2.27. This relatively low multiple may signal that Q32 Bio Inc. is undervalued compared to historical market norms.

Earnings Schedule: Q32 Bio Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -5.36.

Investor FAQ

Does Q32 Bio Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Q32 Bio Inc.?

Q32 Bio Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of 2.78.

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Exchange Ticker
NASDAQ QTTB

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
March 26, 2024 0.060000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion